sulindac has been researched along with Intestinal-Diseases* in 1 studies
1 other study(ies) available for sulindac and Intestinal-Diseases
| Article | Year |
|---|---|
The pro-drug sulindac may reduce the risk of intestinal damage associated with the use of conventional non-steroidal anti-inflammatory drugs.
To test the hypothesis that administration of a non-steroidal anti-inflammatory drug formulated as a pro-drug, inactive as a cyclooxygenase inhibitor until after absorption, might cause less intestinal damage than conventional non-steroidal anti-inflammatory drugs, intestinal permeation to 51Cr-EDTA and mannitol was assessed in healthy volunteers before and after oral treatment for 1 week with either the pro-drug sulindac or the conventional non-steroidal anti-inflammatory drug indomethacin. Indomethacin, but not sulindac, significantly increased intestinal permeation to 51Cr-EDTA and reduced haemoglobin and haematocrit; neither affect mannitol permeation. Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Edetic Acid; Humans; Indomethacin; Intestinal Diseases; Intestinal Mucosa; Intestines; Mannitol; Middle Aged; Permeability; Prodrugs; Sulindac; Urea | 1991 |